Bionomics Limited (BNOX) IPO opens at $22 after pricing at $12.35

Today's IPO for Bionomics Limited (NASDAQ: BNOX) opens at $22 after pricing 1,622,000 American Depositary Shares (ADSs) at $12.35.

Evercore ISI and William Blair are acting as lead book-running managers for the Offering. Cantor, Berenberg and H.C. Wainwright & Co. are acting as book-running managers for the Offering.

Bionomics is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder and chronic treatment of Post-Traumatic Stress Disorder. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

You May Also Be Interested In

• Goldman, BofA vie to manage Anthropic employee wealth post-IPO - report
• Agomab adds two members to its board of directors
• ARC Group to acquire Malaysia's Firstborn Top Capital in $1.09B deal